CoLucid Company Press Kit
The CoLucid Company Press Kit is designed to help journalists and other media members research our company for background information or follow-up stories. It contains information about CoLucid's background, its current pipeline and includes information about lasmiditan, a first in class drug that penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.
Logo
CoLucid has made their logo available in a high resolution format for easy media access.
Press Releases
-
CoLucid Pharmaceuticals to Present at the Biotech Showcase during J.P. Morgan Healthcare Conference
Date: January 4, 2012 | Source: PRNewswire
-
CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering
Date: September 29, 2011 | Source:
-
CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
Date: September 9, 2011 | Source: PR Newswire
-
CoLucid Founder Passes Away
Date: September 1, 2011 | Source: PRNewswire
Key Publications
-
5-Hydroxyptryptamine 1 F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks
Date: September 1, 2011 | Source: Cephalalgia
-
Lasmiditan (COL-144) a Selective 5-HT1F agonist, is a rapid & effective oral treatment for acute migraine
Date: September 1, 2011 | Source: European Headache & Migraine Trust Ingernational Congress 2010
-
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan
Date: June 15, 2010 | Source: Cephalalgia
-
Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial
Date: June 15, 2010 | Source: Cephalalgia
About CoLucid
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders.
View CoLucid's Leadership View CoLucid's Scientific Advisors
